关于向 2025 年限制性股票激励计划 激励对象授予限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 鉴于《无锡祥生医疗科技股份有限公司 2025 年限制性股票激励计划（草案）》 （以下简称"《激励计划（草案）》"或"本激励计划"）规定的无锡祥生医疗科技 股份有限公司（以下简称"公司"）2025 年限制性股票授予条件已经成就，根据 公司 2025 年第二次临时股东会授权，公司于 2025 年 10 月 23 日召开了第三届董 事会第十六次会议、第三届董事会薪酬与考核委员会第六次会议，审议通过了《关 于向 2025 年限制性股票激励计划激励对象授予限制性股票的议案》，确定 2025 年 10 月 23 日为授予日，以 16.50 元/股的授予价格向 17 名激励对象授予 160,000 股限制性股票。现将有关事项说明如下： 一、限制性股票授予情况 （一）本次限制性股票授予已履行的决策程序和信息披露情况 证券代码：688358 证券简称：祥生医疗 公告编号：2025-040 无锡祥生医疗科技股份 ...

上海市通力律师事务所 关于无锡祥生医疗科技股份有限公司 2025 年限制性股票激励计 划授予相关事项的法律意见书 致: 无锡祥生医疗科技股份有限公司 敬启者: 上海市通力律师事务所(以下简称"本所")受无锡祥生医疗科技股份有限公司(以下简 称"祥生医疗"或"公司")委托, 指派翁晓健律师、孙文律师(以下简称"本所律师")作为 公司特聘专项法律顾问, 就公司 2025 年限制性股票激励计划(以下简称"本次股权激励计 划")向激励对象授予限制性股票事项(以下简称"本次授予"), 根据《中华人民共和国公司 法》(以下简称"《公司法》")、《中华人民共和国证券法》(以下简称"《证券法》")、《上 市公司股权激励管理办法》(以下简称"《管理办法》")、《上海证券交易所科创板股票上 市规则》(以下简称"《上市规则》")、《科创板上市公司自律监管指南第 4 号——股权激 励信息披露》(以下简称"《股权激励信息披露自律监管指南》")等法律、行政法规和其他 规范性文件(以下简称"法律、法规和规范性文件")和《无锡祥生医疗科技股份有限公司章 程》(以下简称"《公司章程》")的有关规定出具本法律意见书。 为出具本法律意见书, 本所 ...

上海市通力律师事务所 关于无锡祥生医疗科技股份有限公司 2024 年限制性股票激励计 划授予价格调整、首次授予部分第一个归属期符合归属条件及部 分已授予尚未归属限制性股票作废事项之法律意见书 致: 无锡祥生医疗科技股份有限公司 敬启者: 上海市通力律师事务所(以下简称"本所")受无锡祥生医疗科技股份有限公司(以下简 称"祥生医疗"或"公司")委托, 指派翁晓健律师、孙文律师(以下简称"本所律师")作为 公司特聘专项法律顾问, 就公司 2024 年限制性股票激励计划(以下简称"本次激励计划") 授予价格调整(以下简称"本次调整")、首次授予部分第一个归属期符合归属条件(以下简 称"本次归属")及部分已授予尚未归属限制性股票作废(以下简称"本次作废")事项, 根据 《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》(以下 简称"《证券法》")、《上市公司股权激励管理办法》(以下简称"《管理办法》")、《上 海证券交易所科创板股票上市规则》(以下简称"《上市规则》")、《科创板上市公司自律 监管指南第 4 号——股权激励信息披露》(以下简称"《股权激励信息披露自律监管指南》") 等法律、行 ...

证券代码：688358 证券简称：祥生医疗 公告编号：2025-041 无锡祥生医疗科技股份有限公司 第三届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况： 无锡祥生医疗科技股份有限公司（以下简称"祥生医疗"或"公司" ）于 2025 年 10 月 23 日以现场结合通讯表决方式召开了第三届董事会第十六次会议（以下 简称"本次会议"）。公司于 2025 年 10 月 17 日以邮件及通讯方式向全体董事发出 召开本次会议的通知，与会的各位董事已知悉与所议事项相关的必要信息。会议 由公司董事长莫若理女士召集并主持，会议应出席董事 6 人，实际到会董事 6 人，会议的召集和召开程序符合《中华人民共和国公司法》（以下简称"《公司法》"） 等法律、法规、部门规章以及《无锡祥生医疗科技股份有限公司章程》（以下简 称"《公司章程》"）的有关规定，作出的决议合法、有效。 会议以投票表决方式审议通过了以下议案： （一）审议通过《关于调整 2024 年限制性股票激励计划授予价格的议案》 因公 ...

董事会薪酬与考核委员会 公司董事会薪酬与考核委员会对本激励计划首次授予部分第一个归属期的 30 名激励对象进行了核查，除 3 名激励对象因离职不符合归属条件，1 名激励对 象因 2024 年个人业绩考核"不合格"当期归属比例为 0%，本次共拟归属 26 名 激励对象，均符合《中华人民共和国公司法》《中华人民共和国证券法》等法律、 法规和规范性文件以及《无锡祥生医疗科技股份有限公司章程》规定的任职资格， 符合《上市公司股权激励管理办法》《上海证券交易所科创板股票上市规则》等 法律、法规和规范性文件规定的激励对象条件，符合本激励计划规定的激励对象 范围，其作为公司本激励计划激励对象的主体资格合法、有效。上述事项符合相 关法律、法规及规范性文件所规定的条件，不存在损害公司及全体股东利益的情 形。因此，董事会薪酬与考核委员会同意符合归属条件的 26 名激励对象办理归 属，可归属的限制性股票数量为 100,860 股。 特此公告。 无锡祥生医疗科技股份有限公司 无锡祥生医疗科技股份有限公司 董事会薪酬与考核委员会 关于 2024 年限制性股票激励计划首次授予部分 第一个归属期归属名单的核查意见 无锡祥生医疗科技股份有限 ...

Core Insights - The recent announcement from Xiangsheng Medical (688358.SH) reveals a significant change in its top ten circulating shareholders, with major global financial institutions like UBS AG and Barclays Bank PLC now included, indicating increased international interest in the company [1][2]. Group 1: Shareholder Changes - The latest data shows a notable shift in Xiangsheng Medical's top ten circulating shareholders, with UBS AG and Barclays Bank PLC becoming the eighth and ninth largest shareholders, respectively [2][3]. - This change reflects a growing recognition of Xiangsheng Medical's investment value by global capital, as these institutions have chosen to increase or establish positions in the company [2][3]. Group 2: Reasons for Foreign Investment - The influx of foreign capital is attributed to a thorough assessment of Xiangsheng Medical's fundamentals and the promising outlook of the ultrasound medical imaging sector [3]. - Xiangsheng Medical is a leading player in the ultrasound medical imaging equipment market, with a strong focus on R&D, production, and sales, which aligns with foreign investors' preference for high-quality growth stocks [3]. - The medical device sector is seen as a lucrative opportunity due to the global aging trend and increasing healthcare demands, with Xiangsheng Medical's products being competitive both domestically and internationally [3]. Group 3: Market Impact - The entry of major foreign investors like UBS and Barclays sends a strong positive signal to the market, enhancing confidence in Xiangsheng Medical's intrinsic value and growth potential [4]. - This development is expected to attract more domestic institutional and individual investors, creating a synergistic effect on capital inflow [4]. - The inclusion of well-known foreign institutions in the shareholder list elevates Xiangsheng Medical's market visibility and liquidity, providing an "international certification" that boosts its reputation in the capital market [4].

Market Performance - The medical device sector increased by 1.01% on October 21, with Botao Bio leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Top Gainers - Botao Bio (688767) closed at 43.39, up 8.12% with a trading volume of 50,200 shares and a transaction value of 216 million [1] - Xiangsheng Medical (688358) closed at 34.93, up 6.62% with a trading volume of 45,600 shares and a transaction value of 157 million [1] - Hualan Biological (301093) closed at 39.30, up 6.53% with a trading volume of 57,500 shares and a transaction value of 223 million [1] Top Losers - Jinhao Medical (920925) closed at 31.85, down 2.24% with a trading volume of 11,900 shares and a transaction value of 37.83 million [2] - Toukeng Life (300642) closed at 26.75, down 2.01% with a trading volume of 162,300 shares and a transaction value of 44.4 million [2] - Maillande (688273) closed at 40.48, down 1.99% with a trading volume of 22,300 shares and a transaction value of 90.15 million [2] Capital Flow - The medical device sector experienced a net outflow of 229 million from institutional investors and 168 million from retail investors, while retail investors saw a net inflow of 397 million [2][3] - Notable capital inflows included Xinhua Medical with a net inflow of 24.93 million from institutional investors [3] - Hualan Biological had a net inflow of 20.37 million from institutional investors, despite a net outflow from retail investors [3]

Core Viewpoint - Xiangsheng Medical (688358) reported a significant increase in net profit for Q3 2025, primarily due to improved exchange gains, despite a decline in revenue for the first three quarters of the year [1][2][3] Trading Information Summary - On October 20, 2025, the stock closed at 32.76 yuan, up 0.43%, with a turnover rate of 2.2% and a trading volume of 24,600 shares, amounting to a total transaction value of 81.94 million yuan [1] - The net outflow of main funds was 550.79 thousand yuan, accounting for 6.72% of the total transaction value, while retail investors saw a net inflow of 649.32 thousand yuan, representing 7.92% of the total [2] Shareholder and Capital Changes - As of September 30, 2025, the number of shareholders decreased to 6,167, a decline of 7.0% from June 30, 2025, with the average shareholding increasing to 18,200 shares [1][2] - The average market value of shares held per account was 598,200 yuan [1] Performance Disclosure Highlights - For the first three quarters of 2025, the company achieved a revenue of 343 million yuan, a decrease of 5.27% year-on-year, with Q3 revenue at 107 million yuan, down 6.68% [3] - The net profit attributable to shareholders for the first three quarters was 93.92 million yuan, a decline of 4.56%, while Q3 net profit was 24.22 million yuan, showing a year-on-year increase of 41.95% [3] - The non-recurring net profit for the first three quarters was 86.97 million yuan, down 2.69%, with Q3 showing a significant increase of 53.63% [3] - The weighted average return on equity was 6.63%, a decrease of 0.51 percentage points year-on-year, while Q3 saw an increase to 1.74%, up 0.49 percentage points [3] - R&D investment for the first three quarters totaled 56.57 million yuan, down 8.40%, representing 16.48% of revenue, a decrease of 0.57 percentage points [3] - The net cash flow from operating activities was 73.29 million yuan, an increase of 3.78% [3] - The total number of ordinary shareholders at the end of the reporting period was 6,167 [3] - The top two shareholders, Wuxi Xiangsheng Investment Co., Ltd. and Mo Ruoli, hold 40.46% and 23.60% respectively, and are considered acting in concert [3]

Core Insights - On October 20, a total of 8 companies released their Q3 2025 financial reports, with 4 companies reporting year-on-year profit growth and 4 reporting declines [1] - Among these companies, 6 reported year-on-year revenue growth, while 2 experienced declines [1] - Companies that saw simultaneous growth in both net profit and revenue include Xingwang Yuda and two others, while Xiangsheng Medical reported declines in both metrics [1] - The company with the highest profit growth rate was Xingwang Yuda, achieving a remarkable increase of 260.00% [1] Company Performance Summary - **Xingwang Yuda (002829)** - Earnings per share: 0.1800 CNY - Net profit: 38.37 million CNY - Net profit year-on-year growth: 260.00% - Revenue: 266.43 million CNY - Revenue year-on-year growth: 14.97% [1] - **Yangjie Technology (300373)** - Earnings per share: 1.8557 CNY - Net profit: 973.61 million CNY - Net profit year-on-year growth: 45.51% - Revenue: 5347.74 million CNY - Revenue year-on-year growth: 20.89% [1] - **Darui Electric (300976)** - Earnings per share: 1.7500 CNY - Net profit: 231.02 million CNY - Net profit year-on-year growth: 26.84% - Revenue: 2278.36 million CNY - Revenue year-on-year growth: 28.59% [1] - **Huiquan Brewery (600573)** - Earnings per share: 0.3940 CNY - Net profit: 98.56 million CNY - Net profit year-on-year growth: 23.70% - Revenue: 575.73 million CNY - Revenue year-on-year growth: -2.59% [1] - **Xiangsheng Medical (688358)** - Earnings per share: 0.8400 CNY - Net profit: 93.92 million CNY - Net profit year-on-year growth: -4.56% - Revenue: 343.17 million CNY - Revenue year-on-year growth: -5.27% [1] - **Xiangfenghua (300890)** - Earnings per share: 0.1676 CNY - Net profit: 19.95 million CNY - Net profit year-on-year growth: -64.64% - Revenue: 1130.90 million CNY - Revenue year-on-year growth: 8.16% [1] - **Tongyou Technology (300302)** - Earnings per share: 0.0194 CNY - Net profit: 0.93 million CNY - Net profit year-on-year growth: -70.37% - Revenue: 32.72 million CNY - Revenue year-on-year growth: 7.73% [1] - **Shenglong Shares (603178)** - Earnings per share: -0.3100 CNY - Net profit: -72.95 million CNY - Net profit year-on-year growth: -1163.12% - Revenue: 1253.80 million CNY - Revenue year-on-year growth: 10.35% [1]

Core Insights - Xiangsheng Medical Technology Co., Ltd. reported a revenue of 107 million yuan and a net profit of 24.22 million yuan for Q3 2025, marking a year-on-year increase of 41.95% in net profit [2] - The company has maintained a strong focus on R&D, with an investment of 56.57 million yuan in the first three quarters of 2025, representing 16.48% of revenue [3] - Xiangsheng Medical has expanded its technology matrix to 63 core technologies, emphasizing advancements in ultrasound AI and image processing [3] Financial Performance - For the first three quarters of 2025, the company achieved a total revenue of 343 million yuan and a net profit of 93.92 million yuan, with a year-on-year increase of 3.78% in cash flow from operating activities [4] R&D and Innovation - The company has introduced new ultrasound AI technologies, including intelligent navigation and guidance, which enhance the standardization of examinations and reduce diagnostic errors [3] - Xiangsheng Medical's R&D investment in Q3 2025 was 18.96 million yuan, accounting for 17.71% of its revenue for that quarter [3] Global Expansion - The company has received 43 new foreign market access licenses in the first half of 2025, with products now covering over 30% of tertiary hospitals in China and being exported to over 100 countries and regions [3] AI Integration - Xiangsheng Medical is accelerating the application of AI technologies across various fields, including cardiac ultrasound and obstetric ultrasound, with the launch of the SonoAI solution that covers multiple clinical applications [6] - The company has developed an AI-assisted breast cancer screening robot, which has received medical device testing reports, providing a new pathway for efficient and standardized early screening [6]